摘要
脂肪性肝病(fatty liver disease,FLD),简称脂肪肝,是临床常见的遗传-环境-代谢应激性肝脏疾病.临床上主要分为酒精性脂肪肝和非酒精性脂肪肝.若未进行积极干预,该病可进展为肝纤维化、肝硬化,甚至肝癌.他汀类药物,即3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂(3-hydroxy-3-methylglutaryl-coenzyme A,HMG-CoA),通过抑制HMG-CoA的活性,显著降低血清胆固醇水平,临床常用于高胆固醇血症的治疗.有研究指出他汀类药物还具有抗炎、抗氧化、抗纤维化等作用,可能对FLD具有一定疗效.本文通过回顾现有他汀类药物治疗FLD的临床相关证据以指导临床用药.
Fatty liver disease(FLD),a common liver disease,is caused by genetic,environmental,and metabolic factors.It is mainly divided into alcoholic fatty liver disease and nonalcoholic fatty liver disease.FLD will gradually progress to liver fibrosis,cirrhosis,and even liver cancer if there is no timely intervention.Statins,3-hydroxy-3-methylglutaryl coenzyme A(HMG-CoA)reductase inhibitors,can significantly decrease serum cholesterol levels by inhibiting the activity of HMG-CoA reductase.Thus,they are widely used to treat hypercholesterolemia in clinical practice.Some studies have reported that statins may exert anti-inflammatory,anti-oxidation,and anti-fibrosis effects,suggesting their benefits on FLD.Herein,we review the existing evidence about use of statins for the treatment of FLD to further guide the rational use of statins in patients with FLD.
作者
方晓慧
王彩娥
邓娇
祁兴顺
Xiao-Hui Fang;Cai-E Wang;Jiao Deng;Xing-Shun Qi(Department of Gastroenterology,General Hospital of Northern Theater Command,Shenyang 110840,Liaoning Province,China;Department of Life Sciences and Biopharmaceutics,Shenyang Pharmaceutical University,Shenyang 110016,Liaoning Province,China;Department of Pharmacy,General Hospital of Northern Theater Command,Shenyang 110840,Liaoning Province,China)
出处
《世界华人消化杂志》
CAS
2023年第16期659-665,共7页
World Chinese Journal of Digestology
